Tresiba for Adolescents (Ages 12 to 17): School and Activity Considerations

Why Insulin Degludec Behaves Differently in Teenagers

Insulin degludec's pharmacokinetic profile sets it apart from other basal insulins, and that difference shapes every school-day decision. Its half-life of roughly 25 hours produces a flat, peakless action curve that persists beyond 42 hours after a single dose, which means there is no predictable "peak window" during which hypoglycemia risk spikes the way it might with NPH insulin. [1]

Adolescent physiology adds complexity. Puberty-driven surges in growth hormone and insulin-like growth factor-1 create significant day-to-day insulin resistance, sometimes requiring 30 to 50% higher weight-based doses than adults. The BEGIN YOUNG 1 trial (N=350 children and adolescents with type 1 diabetes) demonstrated that degludec achieved non-inferior HbA1c reduction compared to insulin detemir while producing significantly fewer confirmed hypoglycemic episodes overnight, specifically 36% fewer nocturnal hypoglycemia events (P<0.001). [2]

Peakless Pharmacology and What It Means in Class

A peakless basal insulin is reassuring during a geometry test. There is no predictable 6-to-8-hour trough to anticipate. But the flip side is that any dose change takes 2 to 3 days to reach a new steady state because of the long half-life. A dose increase given Monday morning will not fully express itself until Wednesday. Clinicians should build that lag into any school-week titration plan.

Puberty, Insulin Resistance, and Dosing Variability

Tanner stage progression creates meaningful variance in total daily insulin requirements. A 14-year-old in Tanner stage 3 may need 0.8 to 1.2 U/kg/day total insulin, while the same patient at Tanner stage 5 at age 17 may need considerably less. The ADA Standards of Care recommend reviewing basal-to-bolus ratios at every visit for adolescents with type 1 diabetes, targeting a basal fraction near 40 to 50% of total daily dose. [3]

Timing Insulin Degludec Around the School Schedule

Degludec can be injected at any time of day, but consistency matters. The FDA-approved label states the injection time can shift by up to 8 to 9 hours without clinically meaningful pharmacokinetic disruption. [4] That flexibility benefits teenagers whose morning routines are unpredictable, but it should not be read as permission for truly erratic timing.

Choosing Morning Versus Evening Administration

Most adolescents do well with a fixed morning injection before school, taken at the same time as breakfast bolus insulin. This approach keeps the entire diabetes routine in one predictable window and avoids the risk of a forgotten evening dose when after-school activities, homework, or social plans compete for attention.

Evening dosing works for some families, particularly those managing dawn phenomenon (early-morning glucose rise driven by cortisol and growth hormone). An evening degludec injection places peak steady-state coverage closer to the early-morning hours. Discuss the tradeoffs with your endocrinologist, and once the time is chosen, document it in the school health plan.

Dose-Shift Protocol When Schedules Change

Weekends, holidays, and exam-week schedule changes all shift injection timing. The ADA recommends that if a dose is more than 8 hours late, patients should take it as soon as they remember and then return to the scheduled time the following day, not double-dose. [3] Schools should have a written copy of this protocol so the nurse is not improvising during a Monday-morning exception.

Physical Activity, Sports, and Exercise-Induced Hypoglycemia

Exercise is one of the highest-risk situations for adolescents using any basal-bolus insulin regimen. Aerobic activity increases glucose uptake by skeletal muscle through an insulin-independent GLUT4 pathway, meaning glucose can fall even when basal insulin levels seem appropriate. [5]

Because degludec cannot be "removed" the way a pump basal rate can be suspended, the management approach relies on three levers: pre-exercise carbohydrate supplementation, post-exercise monitoring, and planned basal dose reduction on known high-activity days.

Pre-Exercise Carbohydrate Strategy

The ADA and International Society for Pediatric and Adolescent Diabetes (ISPAD) recommend consuming 15 to 30 g of rapid-acting carbohydrates before aerobic exercise lasting more than 30 minutes if the starting glucose is below 126 mg/dL (7 mmol/L). [3] For a teenager heading to a 90-minute soccer practice after last period, this typically means a snack at the 3:00 PM class break.

Resistance training and high-intensity interval sports (sprint drills, wrestling) carry a different risk profile: they can temporarily raise glucose via catecholamine-driven hepatic glucose output before causing a delayed drop several hours later. Teens in these sports may not feel a low during practice but can experience significant hypoglycemia at 10:00 PM or during the night.

Planned Basal Dose Reduction on Athletic Days

A 10 to 20% reduction in the degludec dose on days with planned prolonged aerobic activity is supported by clinical guidance from both ISPAD and the ADA. [6] Because degludec's steady state spans multiple days, the reduction should ideally be applied the day before a major competition or tournament, not the morning of. Parents and coaches should understand this lead-time principle.

The BEGIN YOUNG 1 trial reported that the rate of severe hypoglycemia requiring third-party assistance was numerically lower in the degludec arm versus detemir (0.06 vs. 0.11 episodes per patient-year), though the trial was not powered to demonstrate statistical significance for that endpoint. [2]

Post-Exercise Monitoring Protocol

Glucose monitoring should occur immediately after exercise, at the 2-hour mark, and again before bed on high-activity days. Continuous glucose monitoring (CGM) reduces missed nocturnal lows substantially. A 2023 randomized trial in adolescents with type 1 diabetes showed that CGM use reduced time below range (defined as glucose <70 mg/dL) by 1.2 percentage points compared to self-monitoring of blood glucose (P<0.001). [7]

School Documentation: IHP, Section 504, and the Diabetes Medical Management Plan

A written legal framework at school is non-negotiable for any adolescent on insulin. Three document types are relevant.

Individual Health Plan (IHP)

The IHP is a nursing document prepared by the school nurse in collaboration with the family and endocrinology team. It should specify the degludec dose and injection time, the student's target glucose range (typically 80 to 180 mg/dL during school hours per ADA), the hypoglycemia treatment protocol, and who is authorized to administer glucagon or give a correction bolus. [3]

Section 504 Plan

Section 504 of the Rehabilitation Act of 1973 requires schools to provide accommodations that give students with disabilities equal access to education. For an adolescent with type 1 diabetes, this may include unrestricted access to glucose monitoring during class, permission to carry fast-acting carbohydrates, a designated private space for injections, and extended time on standardized tests when glucose is outside target range. The American Diabetes Association provides a model 504 plan template that endocrinology offices can adapt. [8]

Diabetes Medical Management Plan (DMMP)

The DMMP is a physician-signed document that authorizes specific medical actions at school. It should list the degludec product name and concentration (Tresiba 100 U/mL or 200 U/mL), the FlexTouch pen dose in units, the timing of administration, and the response protocol for glucose readings below 70 mg/dL, below 54 mg/dL, and above 300 mg/dL. Many states require a DMMP as the legal prerequisite for school staff to assist with insulin administration.

The HealthRX clinical team recommends a three-tier escalation framework built into every DMMP for degludec-using adolescents:

• Tier 1 (glucose 70 to 80 mg/dL, asymptomatic): 15 g fast-acting carbs, recheck in 15 minutes, notify parent.
• Tier 2 (glucose <70 mg/dL or symptomatic): 15 to 30 g fast-acting carbs, student stays with nurse, recheck in 15 minutes, parent called immediately.
• Tier 3 (glucose <54 mg/dL, altered consciousness, or unable to swallow): Glucagon administered per order (1 mg IM/SC for weight above 25 kg, or nasal glucagon 3 mg), call 911, then notify parent.

This three-tier structure mirrors the ADA's hypoglycemia classification (Level 1, 2, and 3) and gives school staff a clear decision path. [3]

Hypoglycemia Recognition and Response in the Classroom

Adolescents often mask hypoglycemia symptoms, either because symptoms are subtle at Tanner stage 4 to 5 or because teenagers deliberately avoid drawing attention to themselves. Studies show that hypoglycemia unawareness affects approximately 20 to 25% of adolescents with type 1 diabetes of more than 5 years' duration. [9]

Symptom Profiles That Teachers Should Recognize

Classic adrenergic symptoms (shakiness, sweatiness, pallor, rapid heartbeat) may be absent in teens with hypoglycemia unawareness. Neuroglycopenic symptoms (difficulty concentrating, irritability, confusion, slurred speech) are often the first visible sign. Teachers who know a student uses insulin should be told to take any sudden behavioral or cognitive change seriously until glucose is checked.

Glucagon Availability at School

Every adolescent on basal-bolus insulin should have a glucagon kit or nasal glucagon (Baqsimi 3 mg) stored at school. Nasal glucagon does not require reconstitution and can be administered by any trained adult, making it practical for a classroom or gymnasium setting. The FDA approved Baqsimi in July 2019, and a 2020 pediatric study confirmed non-inferiority to injectable glucagon for treating severe hypoglycemia in patients aged 4 years and older. [10]

Storing Tresiba at School

Insulin degludec is stable at room temperature (below 30°C / 86°F) for up to 56 days after the pen is first used. [4] An unopened Tresiba pen must be refrigerated (2 to 8°C / 36 to 46°F) until the first use. At school, the pen-in-use can be kept in a locked cabinet in the nurse's office at ambient temperature, provided the room stays below 86°F and the pen is kept away from direct sunlight and heat sources.

Do not freeze Tresiba at any point. Frozen insulin degrades and cannot be trusted for dose accuracy. If a pen has been accidentally frozen, it should be discarded.

The nurse's supply log should record the date of first use. A new pen opened on September 1st expires for school use by October 27th regardless of remaining units.

Continuous Glucose Monitoring Integration With Degludec in School

CGM technology is now standard of care for most adolescents with type 1 diabetes. The ADA's Standards of Diabetes Care state that CGM should be offered to all people with type 1 diabetes who are capable of using the device safely. [3] At school, a CGM provides four specific advantages over fingerstick-only monitoring.

First, trend arrows allow the student and nurse to anticipate direction of glucose change before a low triggers symptoms. Second, predictive low alerts (set at 80 to 85 mg/dL) give a 20-minute warning window to act before glucose crosses the 70 mg/dL threshold. Third, share features allow parents and the school nurse to receive real-time data remotely. Fourth, CGM data exports give the endocrinology team visibility into patterns that occur exclusively during school hours, such as post-lunch spikes or gym-class lows, without relying on the teenager to remember or report them.

Alarms, Classroom Etiquette, and School Policy

CGM alarm sounds can create classroom disruption. Most devices allow vibration-only mode or a wrist-worn receiver that keeps alerts private. The student's 504 plan should explicitly state that the student is permitted to respond to CGM alerts without asking permission to leave the classroom.

Communicating With Coaches and Athletic Staff

Coaches interact with adolescent athletes for 2 to 3 hours per day during sports seasons, often without a school nurse present. A brief written summary (one page maximum) should accompany any student-athlete using Tresiba. It should include: the student's name and emergency contact, confirmation that a hypoglycemia kit is kept in the sports bag, the glucose thresholds for safe participation (most guidelines recommend not exercising if glucose is <90 mg/dL or above 270 mg/dL with urine or blood ketones), and the Tier 1/2/3 response protocol described above.

The American Diabetes Association's position statement on diabetes and exercise notes that exercise should be delayed if blood glucose is above 270 mg/dL and ketones are present. [11] Coaches need to understand that this is not a character issue. It is a physiology issue.

Practical Titration Guidance During the School Year

Because degludec's 2 to 3-day steady-state lag means dose changes take time to express, titrations should not happen mid-week before a high-stakes exam or a major athletic event. The HealthRX clinical team recommends initiating any basal dose change on a Thursday or Friday so the new steady state is reached by Monday morning, when the school week begins.

The FDA-approved starting dose for adolescents transitioning from another basal insulin to degludec is unit-for-unit substitution, followed by titration to a fasting glucose target of 80 to 130 mg/dL. [4] The SWITCH PRO trial demonstrated that patients switching from insulin glargine U100 to degludec experienced a statistically significant reduction in overall symptomatic hypoglycemia (rate ratio 0.79, 95% CI 0.70 to 0.89, P<0.001) while maintaining similar HbA1c levels. [12] That reduction in hypoglycemia frequency has real relevance for school performance and classroom safety.

A conservative titration schedule for school-age adolescents: increase or decrease the degludec dose by 2 units every 3 days based on the mean of 3 consecutive fasting glucose readings, targeting 80 to 130 mg/dL. Do not adjust more frequently than every 3 days.